.png)
WEB予約
LINE予約
WEB予約
LINE予約
STD
Hepatitis C is a bloodborne liver infection caused by the hepatitis C virus (HCV). It progresses silently with few symptoms, gradually evolving over 20-30 years into liver cirrhosis and hepatocellular carcinoma (HCC) – a true silent disease. Today, oral Direct-Acting Antiviral (DAA) therapy taken for 8-12 weeks can achieve viral clearance (SVR) in over 95% of patients with minimal side effects, ushering in a new era where Hepatitis C can be cured. This article provides a physician-led comprehensive guide to HCV transmission routes, high-risk behaviors common in men, symptoms, testing methods, the latest DAA treatments, and the risks of leaving the infection untreated, including progression to liver cancer.
Table of Contents
Considering Hepatitis C testing or treatment? | HCV antibody testing & latest DAA therapy available – Men-only clinic – First consultation free
LINEConsult about Hepatitis C testing
*Our physicians will explain treatment plans and costs based on your test results. *LINE communication is for guidance only and not a medical diagnosis.
My liver enzymes came back abnormal, but I have no symptoms, or I am worried because I had a tattoo or blood transfusion in the past – if any of this resonates, you may need to be checked for hepatitis C virus (HCV) infection.
Hepatitis C is widely known as a silent disease because most people experience no symptoms for 20 years or more after infection. Japan has an estimated 1 to 1.5 million HCV carriers, and approximately 70% remain unaware of their infection. Left undetected, HCV can progress fatally through chronic hepatitis to liver fibrosis to liver cirrhosis to hepatocellular carcinoma (HCC).
Thanks to medical advances, oral Direct-Acting Antivirals (DAAs) introduced in 2014 can now eliminate the virus in over 95% of cases (SVR: Sustained Virologic Response) with just 8-12 weeks of treatment, with far fewer side effects than the older interferon-based therapy. With early detection and treatment, Hepatitis C has become a curable disease.
This article offers a comprehensive physician-led explanation of HCV basics, transmission, differences from Hepatitis B, high-risk behaviors in men, symptoms, testing, treatment, and the risks of leaving infection untreated – written by physicians who provide our STI clinic services.
Hepatitis C is liver inflammation caused by infection with the Hepatitis C Virus (HCV). HCV is an RNA virus belonging to the genus Hepacivirus within the Flaviviridae family. It replicates inside human hepatocytes (liver cells), causing chronic inflammation and fibrosis.
A key feature of HCV is that it rarely clears spontaneously and has a high rate of chronicity. Even when acute hepatitis develops, approximately 70% of cases become chronic and can progress to liver cirrhosis or hepatocellular carcinoma over 20-30 years. In contrast, when hepatitis B virus (HBV) is first acquired in adulthood, more than 90% of cases resolve naturally – a significant difference between the two viruses.
The hepatitis C virus is primarily transmitted through blood. Sexual and mother-to-child transmission occur less frequently than with hepatitis B; instead, past medical procedures and blood-contact activities pose the greatest risk. Most HCV carriers in Japan were infected via blood transfusions or blood products before HCV was identified in 1989, or via shared injection equipment used in older medical practices.
While sexual transmission of HCV is less efficient than HBV, risk rises in HIV-positive individuals and those engaging in anal intercourse. Including HCV testing as part of a standard STI screening panel is recommended.
Hepatitis C symptoms vary significantly depending on the stage of infection. In most cases there are few or no symptoms, and HCV is typically discovered incidentally during health checkups or blood donation screening.
It is dangerous to assume no symptoms means no problem. Detecting and treating Hepatitis C during the chronic phase can prevent progression to cirrhosis and liver cancer, so anyone with a history of risk behaviors should be tested as early as possible.
Hepatitis C diagnosis involves a stepwise process of screening followed by confirmatory testing. Since it can be diagnosed via blood tests alone, the typical workflow is blood draw at outpatient visit, with results explained on a follow-up appointment.
This first-line blood test checks for the presence of HCV antibodies. A positive result indicates current or past HCV infection. However, antibody positivity does not always mean current infection – it remains positive even in cases of spontaneous clearance or after successful treatment.
For antibody-positive patients, this test measures the presence and level of HCV viral RNA in the blood using RT-PCR or real-time PCR. Detection of HCV RNA confirms ongoing persistent infection and qualifies the patient for treatment.
HCV is classified into 6 major genotypes (1-6), and treatment choice and duration depend on the genotype. In Japan, genotype 1b accounts for about 70%, 2a for around 20%, and 2b for approximately 10%.
A comprehensive evaluation includes AST/ALT, ALP, GGT, platelet count, albumin, and PT-INR. Additional fibrosis scoring tools such as Fib-4 index or APRI – and when needed, FibroScan (liver stiffness measurement) or liver biopsy – help assess the extent of fibrosis.
Men's Care Clinic offers HCV testing alongside our STI testing services. If you are concerned about possible exposure, feel free to consult our physicians.
Hepatitis C treatment has come a long way since the interferon era. The current standard is oral Direct-Acting Antiviral (DAA) therapy, which achieves SVR (sustained viral clearance) in over 95% of patients after just 8-12 weeks of treatment.
In Japan, DAA therapy for Hepatitis C is covered by the Special Hepatitis Treatment Promotion Program (Ministry of Health, Labour and Welfare). Depending on income, the patient's monthly out-of-pocket cost is capped at either approximately ¥10,000 or ¥20,000, dramatically reducing drug costs that would otherwise reach millions of yen per year under standard 30% co-pay.
Stories of patients fully cured by DAA therapy continue to grow, and Hepatitis C is no longer a chronic illness – it is a curable disease.
The typical natural course of untreated Hepatitis C is chronic hepatitis to liver fibrosis to liver cirrhosis to hepatocellular carcinoma. In Japan, approximately 60% of hepatocellular carcinoma cases are attributed to HCV, meaning the risk of leaving it untreated is far from negligible.
HCV infection affects more than just the liver. It can drive systemic chronic inflammation and trigger a range of extrahepatic manifestations.
Many of these conditions improve after achieving SVR with DAA therapy, making treatment important not only for the liver but for whole-body health.
There is no vaccine against Hepatitis C. Because of the high mutability of HCV, developing an effective vaccine has proven difficult. Therefore, prevention relies entirely on blocking the routes of transmission.
In particular, anyone who received transfusions or blood products before 1992 is strongly encouraged to be tested for HCV. Many municipalities and public health centers in Japan offer free hepatitis virus testing.
At Men's Care Clinic, we provide Hepatitis C testing, diagnosis, and referral coordination in a calm, male-only clinical environment. HCV testing can be added to your STI screening panel upon request.
I have a history of blood transfusions, My health checkup showed abnormal liver function, or I am worried about STIs and want to be checked for hepatitis too – whatever your concern, our physicians are here to help.
Hepatitis C testing, treatment referral, and subsidy guidance | First consultation free – Men-only clinic – 3 locations
*Our physicians will explain testing, treatment plans, and costs. *LINE communication is for guidance only and not a medical diagnosis.
Yes. After completing DAA therapy and achieving SVR (HCV undetectable 12 weeks after end of treatment), the infection is virologically considered cured. HCV reactivation after SVR is extremely rare, and 95-99% of patients can be cured. However, even after SVR, the risk of hepatocellular carcinoma persists, so ongoing follow-up imaging is essential.
Hepatitis C is a silent disease with virtually no symptoms during the chronic phase. If you have a history of risk behaviors or abnormal liver function on a health checkup, testing is recommended regardless of symptoms. Treatment before symptoms emerge can prevent progression to cirrhosis and liver cancer.
The sexual transmission risk is relatively low, at around 1-3%. However, the risk increases in HIV-positive individuals, MSM, or those engaging in anal intercourse, so caution is warranted. Including HCV testing as part of an STI screening panel is recommended.
Compared to historic interferon therapy, DAA side effects are dramatically reduced. The most common are mild headache, fatigue, and nausea – manageable enough that most patients continue their daily life and work without disruption. Serious adverse events occur in fewer than 1% of cases.
Under standard 30% co-pay in Japan, DAA medication would normally cost around ¥500,000-¥1,000,000, but with the Special Hepatitis Treatment Promotion Program subsidy, your monthly out-of-pocket cost is capped at approximately ¥10,000 or ¥20,000 depending on income. Applications are processed through your prefectural government office.
A positive antibody result only indicates current or past infection. The HCV-RNA test confirms whether the virus is currently in your body. If RNA is negative, the infection has resolved (spontaneously or via prior treatment), and only observation is needed. If RNA is positive, you qualify for DAA therapy.
Key differences include the chronicity rate, sexual transmission risk, and vaccine availability. With Hepatitis B, more than 90% of adult-acquired infections resolve naturally, but sexual and perinatal transmission risks are high and vaccination is available. Hepatitis C has a chronicity rate of about 70%, low sexual transmission risk, and no vaccine. See our detailed Hepatitis B article for more.
It is important not to miss doses, verify any drug interactions (with certain antiarrhythmics, antacids, statins, and others), and avoid excessive alcohol. Supplements and over-the-counter medications (especially St. John's Wort and antacids) can also cause interactions, so always inform your physician.
The original virus rarely persists after SVR, but infection with a different HCV strain remains possible. Risk behaviors such as sharing needles or sexual activity involving bleeding should still be avoided after treatment. If reinfection occurs, retreatment is possible.
Initial screening (HCV antibody test) is available at STI clinics or general internal medicine clinics. If positive, you will need a gastroenterology or hepatology clinic with specialists who can perform HCV-RNA testing, genotyping, and DAA therapy. At Men's Care Clinic, we provide initial screening and coordinate referrals to specialist centers under one roof.
Hepatitis C is a silent, potentially fatal disease that progresses slowly over 20-30 years – but with today's DAA therapy, more than 95% of patients can achieve a complete cure. It has truly become a curable disease. Early detection and treatment are the only way to prevent progression to cirrhosis and hepatocellular carcinoma.
If you have a history of risk behaviors or have been told you have abnormal liver function, we strongly encourage you to undergo HCV testing without delay.
Related articles: Hepatitis B Treatment and Risks of Leaving It Untreated / Complete Guide to STIs and Symptoms in Men
Hepatitis C testing and treatment referral | First consultation free – Men-only clinic – Available in Shinbashi/Akihabara/Omotesando
LINEBook a free HCV testing consultation
*Available at our Shinbashi, Akihabara, and Omotesando clinics. Online inquiries welcome. *LINE communication is for guidance only and not a medical diagnosis.
This article is medically supervised by our physicians at Men's Care Clinic. The content is based on accurate medical evidence, but please always consult a physician for individual symptoms and treatment decisions.
STD
関連記事
2026/04/16 STD 【医師監修】クラミジアとは？男性の症状・感染経路・検査・治療を徹底解説
2026/04/04 STD 【医師監修】男性の梅毒とは？症状・感染経路・検査・治療を徹底解説
2022/11/07 STD 梅毒の進行ステージと放置リスク｜第1期〜第4期の症状を医師が徹底解説【2026年最新】
2021/09/19 STD 尖圭コンジローマ｜男性の症状・治療・HPVワクチンを医師が徹底解説【2026年最新】
2021/09/19 STD B型肝炎の治療と放置リスク｜HBs抗原・HBVワクチン・核酸アナログ療法を医師が徹底解説【2026年最新】
2021/09/19 STD C型肝炎の治療と放置リスク｜DAA療法でSVR95%超を目指す最新治療を医師が解説【2026年最新】
2021/09/19 STD 男性のトリコモナス｜無症状でもうつる？放置リスクと検査・治療法
2021/05/08 STD マイコプラズマ感染症（男性）｜症状・検査・治療・耐性菌対策まで医師監修で徹底解説
2021/05/05 STD 男性のヘルペス｜性器・口唇の症状・治療・再発予防を医師が徹底解説【2026年最新】
2021/05/02 STD 男性の性器カンジダ症｜亀頭炎・包皮炎の症状・治療・予防を医師が徹底解説【2026年最新】
2026.04.16
STD
【医師監修】クラミジアとは？男性の症状・感染経路・検査・治療を徹底解説
2026.04.04
STD
【医師監修】男性の梅毒とは？症状・感染経路・検査・治療を徹底解説
2022.11.07
STD
梅毒の進行ステージと放置リスク｜第1期〜第4期の症状を医師が徹底解説【2026年最新】
2021.09.19
STD
尖圭コンジローマ｜男性の症状・治療・HPVワクチンを医師が徹底解説【2026年最新】
2021.09.19
STD
B型肝炎の治療と放置リスク｜HBs抗原・HBVワクチン・核酸アナログ療法を医師が徹底解説【2026年最新】
2021.09.19
STD
C型肝炎の治療と放置リスク｜DAA療法でSVR95%超を目指す最新治療を医師が解説【2026年最新】
2021.09.19
STD
男性のトリコモナス｜無症状でもうつる？放置リスクと検査・治療法
2021.05.08
STD
マイコプラズマ感染症（男性）｜症状・検査・治療・耐性菌対策まで医師監修で徹底解説
2021.05.05
STD
男性のヘルペス｜性器・口唇の症状・治療・再発予防を医師が徹底解説【2026年最新】
2021.05.02
STD
男性の性器カンジダ症｜亀頭炎・包皮炎の症状・治療・予防を医師が徹底解説【2026年最新】
AGA